Antoniucci D, Valenti R, Santoro G M, Bolognese L, Taddeucci E, Trapani M, Santini A, Fazzini P F
Division of Cardiology, Careggi Hospital, Florence, Italy.
Cathet Cardiovasc Diagn. 1997 May;41(1):14-9. doi: 10.1002/(sici)1097-0304(199705)41:1<14::aid-ccd5>3.0.co;2-d.
The purpose of this study was to evaluate the feasibility, safety, and efficacy of bailout coronary stenting without anticoagulation or intravascular ultrasound guidance in patients with acute or unequivocal threatened closure after conventional angioplasty. One hundred twenty consecutive patients were prospectively enrolled according to the following criteria: 1) acute or threatened closure after balloon angioplasty; 2) reference vessel diameter > or = 2.5 mm. All patients after stent implantation were on antiplatelet treatment with aspirin and ticlopidine. Four types of stents were used: Palmaz-Schatz (J&J), Gianturco-Roubin (Cook), Freedom (Global Therapeutics), and Microstent (AVE). Procedural results: a total of 206 stents were implanted in 134 target lesions with a stent deployment success rate of 100%; 44 target lesions were treated with multiple stent implantation; the mean luminal diameter after stenting was 3.14 +/- 0.34 mm, and the mean final percent diameter stenosis was -2 +/- 10%; the mean balloon to vessel ratio was 1.11 +/- 0.15; the mean final pressure inflation was 13.9 +/- 2.4 atm; an optimal angiographic result was achieved in 128 lesions (96%). In-hospital results: in-hospital recurrent ischemia occurred in 4 patients (3%); recurrent ischemia resulted directly in death in 1 patient, in nonfatal Q-waves infarction in 2 patients, and in emergency coronary artery surgery in 1 patient. Six-month clinical follow-up results: event free survival rate was 77%; 1 patient had non fatal infarction; the incidence of repeat revascularization procedures was 19%; there were no cardiac deaths. Angiographic follow-up results (follow-up rate 93%): the restenosis or reocclusion rate was 28%. Bailout coronary stenting without chronic anticoagulation treatment or intravascular ultrasound guidance may be considered a highly feasible and safe treatment for acute or threatened closure after failed angioplasty.
本研究旨在评估在常规血管成形术后出现急性或明确的有闭塞风险的患者中,不进行抗凝治疗或血管内超声引导下的补救性冠状动脉支架置入术的可行性、安全性和有效性。根据以下标准前瞻性纳入了120例连续患者:1)球囊血管成形术后急性或有闭塞风险;2)参考血管直径≥2.5mm。所有支架植入后的患者均接受阿司匹林和噻氯匹定的抗血小板治疗。使用了四种类型的支架:Palmaz-Schatz(强生公司)、Gianturco-Roubin(库克公司)、Freedom(全球治疗公司)和Microstent(AVE公司)。手术结果:共对134个靶病变植入了206枚支架,支架置入成功率为100%;44个靶病变接受了多支架植入治疗;支架置入后的平均管腔直径为3.14±0.34mm,平均最终直径狭窄百分比为-2±10%;平均球囊与血管直径比为1.11±0.15;平均最终加压膨胀压力为13.9±2.4个大气压;128个病变(96%)获得了最佳血管造影结果。住院结果:4例患者(3%)发生住院期间复发性缺血;复发性缺血直接导致1例患者死亡,2例患者发生非致命性Q波梗死,1例患者接受急诊冠状动脉手术。六个月临床随访结果:无事件生存率为77%;1例患者发生非致命性梗死;重复血运重建手术的发生率为19%;无心脏死亡病例。血管造影随访结果(随访率93%):再狭窄或再闭塞率为28%。对于血管成形术失败后出现的急性或有闭塞风险的情况,可以考虑不进行长期抗凝治疗或血管内超声引导下的补救性冠状动脉支架置入术,这是一种高度可行且安全的治疗方法。